Back to Screener

Healthcare

Santhera Pharmaceuticals Holding AG(SPHDF)

Live Price

Offline

$23.25

+0.00% today

Window Change

+0.00%

Window

May 28, 2026 โ†’ Jun 18, 2026

Market Cap
$240.00M
Revenue Growth
+97.4%
EPS Growth
-2.4%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 16 bars ยท May 28, 2026 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Santhera Pharmaceuticals Holding AG (SPHDF) is a Healthcare stock with a market cap of $240.00M and listed on OTC. The stock last traded around $23.25 and up 0.0% across the available one-year price window (May 28, 2026 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of +97.4%, EPS growth of -2.4%, a dividend yield of 0.0%. What stands out right now is revenue +97.4%, EPS -2.4%, free cash flow +2.4% with operating margin -49.0% and ROIC -34.5%. Valuation is more restrained than many high-expectation growth names at price/sales 3.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SPHDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+97.4% vs +7.6% peer median

Operating Margin

Below sector median

-49.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report was closer to in-line

2026 was reported on Apr 28, 2026 with revenue ahead of estimates by +13.2%.

The operating picture looks softer than before

Revenue is at +97.4% and EPS is at -2.4%, with operating margin around -49.0%.

The next real check-in already has a date

The next earnings event is scheduled for Sep 21, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SPHDF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SPHDF Max Drawdown

0.00%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SPHDF and SPY.

Calendar-year return history is still loading or unavailable.
Santhera Pharmaceuticals Holding AG logo

Company Overview

Santhera Pharmaceuticals Holding AG

Other OTC

Pratteln, CH
Visit santhera.comCall IR41 61 906 89 50

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.

Leadership
Dario Eklund
IPO Date
Apr 17, 2014
Employees
78
Street Address
Hohenrainstrasse 24
Mailing
Pratteln, 4133
Region
Pratteln, CH
Reporting Currency
USD
Investor Line
41 61 906 89 50
Last Updated
May 5, 2026
ISIN: CH1276028821
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
3.1
Price/Book
โ€”

Growth

Revenue
+97.4%
EPS
-2.4%
Free Cash Flow
+2.4%

Profitability

Gross Margin
18.7%
Operating Margin
-49.0%
Net Margin
-63.8%
ROE
684.8%
ROIC
-34.5%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
1.29

Earnings Reports

๐Ÿ“… Next earningsSep 21, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Sep 21, 26
TBD
โ€”
Est โ€”
โ€”
โ€”
Est 59732.3B
โ€”
โ€”
Apr 28, 26
-0.98
Est โ€”
โ€”
67106.5B
Est 59285.8B
+13.2%
โ€”
Apr 29, 25
-2.58
Est โ€”
โ€”
27530.3B
Est 9000.0B
+205.9%
โ€”
Sep 12, 24
-1.50
Est โ€”
โ€”
15752.2B
Est 6228.9B
+152.9%
โ€”
Jun 18, 24
-0.75
Est โ€”
โ€”
7824.8B
Est โ€”
โ€”
โ€”
Apr 25, 24
8.18
Est โ€”
โ€”
116210.2B
Est โ€”
โ€”
โ€”
Sep 30, 23
3.99
Est โ€”
โ€”
54334.8B
Est โ€”
โ€”
โ€”
Jun 30, 23
-2.33
Est โ€”
โ€”
4391.5B
Est โ€”
โ€”
โ€”
Mar 31, 23
-1.14
Est โ€”
โ€”
2153.0B
Est โ€”
โ€”
โ€”
Dec 31, 22
-6.95
Est โ€”
โ€”
1322.4B
Est โ€”
โ€”
โ€”
Sep 30, 22
-3.22
Est โ€”
โ€”
619.7B
Est โ€”
โ€”
โ€”
Jun 30, 22
-5.47
Est โ€”
โ€”
6524.3B
Est โ€”
โ€”
โ€”
Dec 31, 21
-7.72
Est โ€”
โ€”
-6656.5B
Est โ€”
โ€”
โ€”
Jun 30, 21
-9.99
Est โ€”
โ€”
4862.7B
Est โ€”
โ€”
โ€”
Dec 31, 20
-26.03
Est โ€”
โ€”
8180.7B
Est โ€”
โ€”
โ€”
Sep 8, 20
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks